RYZUMVI Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Ryzumvi, and when can generic versions of Ryzumvi launch?

Ryzumvi is a drug marketed by Famygen Life Sci and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-three patent family members in sixteen countries.

The generic ingredient in RYZUMVI is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryzumvi

A generic version of RYZUMVI was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for RYZUMVI?
What are the global sales for RYZUMVI?
What is Average Wholesale Price for RYZUMVI?

Summary for RYZUMVI

International Patents:	23
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in RYZUMVI?	RYZUMVI excipients list
DailyMed Link:	RYZUMVI at DailyMed

Drug patent expirations by year for RYZUMVI

Pharmacology for RYZUMVI

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for RYZUMVI

RYZUMVI is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting RYZUMVI

Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting RYZUMVI

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for RYZUMVI

See the table below for patents covering RYZUMVI around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Singapore	11202104094Y		⤷ Sign Up
Japan	6335927		⤷ Sign Up
Japan	2016506966	フェントラミンの水性点眼液およびそれらの医学的用途	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2014121027		⤷ Sign Up
Canada	3116589		⤷ Sign Up
Australia	2014212274	Aqueous ophthalmic solutions of phentolamine and medical uses thereof	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration